Education Videos & Podcasts List
RNSH Hepatology Education Session
This one hour session brings together expert clinicians from Northern Sydney Local Health District Gastroenterology and Hepatology Team, including the Director of Hepatology, to provide insights into the assessment and management of common liver-related presentations in primary care.
The webinar features concise presentations covering everyday clinical challenges such as abnormal liver enzymes, incidental liver lesions, and interpretation of liver function results.
Presenters discuss key red flags and provide clear guidance on when specialist referral is indicated. It includes an overview of Hepatitis B management, with a focus on the new Hepatitis B Model of Shared Care – highlighting opportunities for GPs to play a central role in ongoing patient management in collaboration with specialist services.
This webinar is ideal for GPs seeking to enhance their confidence in managing liver disease, improve interpretation of investigations, and strengthen collaborative care pathways.
Learning outcomes:
- Identify and assess common liver-related presentations in primary care, including abnormal liver enzymes and incidental liver lesions
- Interpret liver function tests and recognise red flags that warrant further investigation or specialist referral
- Describe the principles of Hepatitis B management and the Shared Care Model, including the role of GPs in ongoing monitoring and collaborative patient care
Speakers:
Dr Cameron Gofton (BSci, MBBS, MPH, FRACP, PhD) – Director of Hepatology Services – Northern Sydney Local Health District, Head of Hepatology – Royal North Shore Hospital
Dr Salim Maher (MBBS, BSc(Hons) FRACP) – Gastroenterology & Hepatology Staff Specialist – Royal North Shore Hospital, Clinical Senior Lecturer – University of Sydney
Clare Lavery – Clinical Nurse Consultant Hepatology Models of Care – Royal North Shore Hospital Target Audience: General practitioners, Practice Nurses, Nurse Practitioner DATE: Wednesday 5 August, 2026
Cardio-renal metabolic syndrome in people with diabetes
This podcast explores the intersection of cardiovascular, renal, and metabolic health, with a focused discussion on cardiovascular disease management and the emerging role of GLP-1 receptor agonists and SGLT2i in lowering cardiovascular and renal risk, alongside strategies for optimising care in patients with renal disease.
The presentation of patient case studies brings these concepts to life, highlighting clinical decision-making and multidisciplinary team approaches.
Learning outcomes:
- Analyse how cardiovascular, renal, and metabolic systems interact in cardiorenal metabolic syndrome and affect outcomes in primary care.
- Evaluate evidence for GLP-1 receptor agonists and SGLT2i in lowering cardiovascular and renal risk and identify appropriate patient use.
- Apply current guidelines to manage patients with cardiovascular disease, diabetes, and chronic kidney disease.
- Use clinical reasoning from GP case studies to guide decisions and improve multidisciplinary care.
- Develop practical management plans combining pharmacological and lifestyle interventions across the cardio-renal metabolic spectrum.
Speakers:
- Professor Greg Fulcher ,VMO. RNSH, Clinical Professor of Medicine, University of Sydney
- Associate Professor Brendon Neuen, Nephrologist and Director, Kidney Trials, Royal North Shore Hospital, Program Lead, Renal and Metabolic Division, The George Institute for Global Health
- Dr Nicola Moll, GP, General Practice Cremorne – Presentation of GP case studies
- Dr Linda Wu, Staff Specialist Endocrinologist, Clinical Senior Lecturer, Royal North Shore Hospital | Concord Hospital | University of Sydney
Cardio-renal metabolic syndrome in people with diabetes
This webinar exploring the intersection of cardiovascular, renal, and metabolic health, with a focused discussion on cardiovascular disease management and the emerging role of GLP-1 receptor agonists and SGLT2i in lowering cardiovascular and renal risk, alongside strategies for optimising care in patients with renal disease.
The presentation of patient case studies will bring these concepts to life, highlighting clinical decision-making and multidisciplinary team approaches.
Speakers:
Prof Greg Fulcher
Assoc Prof Brendon Neuen
Dr Nicola Moll
Cardio-renal metabolic syndrome in people with diabetes
This webinar exploring the intersection of cardiovascular, renal, and metabolic health, with a focused discussion on cardiovascular disease management and the emerging role of GLP-1 receptor agonists and SGLT2i in lowering cardiovascular and renal risk, alongside strategies for optimising care in patients with renal disease.
The presentation of patient case studies will bring these concepts to life, highlighting clinical decision-making and multidisciplinary team approaches.
Speakers:
Prof Greg Fulcher
Assoc Prof Brendon Neuen
Dr Nicola Moll
Current and Emerging Therapies for Osteoarthritis (Professor David Hunter)
Are your osteoarthritis patients stuck in a cycle of ineffective pain management? Are we relying too much on MRIs and surgical referrals instead of treating the whole person?
Today, we are putting an end to the "wear and tear" myth and exploring exciting new and emerging therapies, from holistic core treatments to GLP-1 agonists that will empower your patients and revolutionize your primary care practice.
This episode was originally recorded as a webinar by the Northern Sydney Primary Health Network.
Speakers:
Joining us is Professor David Hunter. Professor Hunter is a rheumatologist clinician-researcher whose primary research focus is clinical and translational research in osteoarthritis. He is ranked as the leading expert in the world on osteoarthritis on expertscape.com, is the section editor for UpToDate osteoarthritis, the co-Editor in Chief for Osteoarthritis and Cartilage, and has over 700 publications in peer-reviewed journals. He hosts the Joint Action Podcast and leads the osteoarthritis team at the Kolling Institute who are dedicated to improving our understanding of osteoarthritis and the quality of life for those who suffer from this prevalent disabling disease. For additional support he can be reached at Naia Health.
Current and Emerging Therapies for Osteoarthritis
Osteoarthritis (OA) affects more than 600 million people worldwide and remains a leading cause of pain, disability, and joint replacement. Despite its enormous burden, current care continues to fall short: core treatments are underused, many patients receive low-value or fragmented care, and available pharmacologic options offer only modest benefit with safety concerns.
Optimising evidence-based foundations—education, weight management, exercise therapy, and psychologically informed care—must remain the first priority. These interventions are highly effective, scalable, and central to preventing treatment failure, yet remain inconsistently implemented across health systems.
At the same time, rapid innovation is reshaping what is possible in OA management.
- Repurposed medications: such as GLP-1 agonists, metformin, and methotrexate show meaningful improvements in pain, function, and potentially disease progression.
- Digital health tools: AI-enabled self-management platforms, and remote monitoring tools are transforming access, adherence, and personalised care.
- Advances in smart drug delivery systems: Rather than just treating symptoms, senolytics and therapies that aim to modify OA by targeting specific molecular mechanisms (Endo-type targeted disease modifying drugs – DMOADs) offer the prospect of precision medicine, with pivotal trials expected in 2026.
The future of OA care will rely on integrating these innovations with optimised core treatment models. Combining behavioural, pharmacological, and technological strategies offers an opportunity to reduce treatment failure, promote equity, and deliver patient-centred, mechanism-aligned care at scale.
Learning outcomes:
- Confidently diagnose osteoarthritis clinically—without unnecessary imaging—determine symptom severity and complexity and identify patients requiring more intensive or multidisciplinary management.
- Apply evidence-based core treatments (education, exercise therapy, weight management, analgesia stewardship) and develop personalised, patient-centred management pathways that improve outcomes and reduce low-value care.
- Evaluate emerging therapeutic options—including repurposed pharmacologic agents, digital self-management tools, and remote monitoring technologies—and integrate appropriate innovations into general practice care.
- Identify barriers to high-value OA care (e.g., misinformation, access, reimbursement) and implement practical strategies to enhance adherence, self-management, and equity in routine general practice.
Speakers:
Professor David Hunter | Florance and Cope Chair of Rheumatology, Professor of Medicine, NHMRC Leadership Investigator Fellow, Sydney Musculoskeletal Health, Kolling Institute, University of Sydney and Rheumatology Department, Royal North Shore Hospital
Resources:
Prefer to listen to this as a Podcast? Click here to access on Spotify
Diabetes in Vulnerable Populations: Practical Approaches in Primary Care
An informative webinar to discuss how to manage diabetes in your most vulnerable patients. Includes two case study presentations with Q & A, the role of the multi-disciplinary team and referral services and practice support available.
Speakers:
- Prof Greg Fulcher, OAM, MBBS, FRACP, Endocrinologist, Clinical Professor of Medicine, University of Sydney
- Dr Margi Coleman, MBBS, DRACOG, FRACGP, General Practitioner
- Dr Stephanie Teoh, MBBS, FRACGP, DRANZCOG, General Practitioner
- Matthew Burton, Pharmacist
Dying at Home
Most Australians prefer to die at home, yet few achieve it. GPs are central to changing this.
This session introduces Full Circle End of Life Matters – a comprehensive end of life team, with physician and nurse led supported model of care designed to partner with general practice. Learn how a fully coordinated, holistic approach can reduce the burden on GPs, improve communication across medical teams, and provide families with seamless end-of-life and grief and bereavement support.
With structured feedback to GPs and clear referral pathways, Full Circle strengthens the community’s ability to support dying at home while easing pressure on overstretched hospital and aged care systems.
TARGET AUDIENCE:
GPs, Practice Staff, Practice Nurses, Allied Health Professonals and Aged Care Staff working in the Northern Sydney Primary Health Network Region
Learning outcomes:
- Strengthening skills in advance care planning and end of life planning and discussion
- Increase confidence in supporting families through dying and bereavement referral
- Understand referral pathways and partnerships that ease burden on general practice
- Access community-based care models that reduce hospital demand and enable patient preference for home death
Speakers:
Dr Clayton Spencer – Medical Director SpencerHealth, MBBS BSc (medicine), Masters Health Admin, Diploma Clinical Psychiatry (Royal Colleges of Physicians and Surgeons Ireland)
Dr Clay Spencer is an experienced senior medical Doctor and has worked in many complex leadership roles over the past twenty years. He has held roles at many levels of public and private organisations including a national role with a large multinational emergency medical retrieval company. He has a background in Psychiatry and General Practice with a particular interest in supporting dying patients.
Anne Kubiak – Full Circle – End of Life Matters
Anne is the founder of Full Circle – End of Life Matters, a pioneering Australian initiative reshaping end-of-life care. With a background as a nurse, death consultant, and health policy innovator, she brings clinical expertise and visionary leadership to compassionate, patient-centred care. Full Circle’s scalable model supports individuals and families through life’s final transitions—physically, emotionally, spiritually, and practically—while integrating seamlessly with existing clinical settings to enhance GP-led care.
Resources:
Referral information can also be sent to NSLHD and HammondCare (who have a formal partnership in place to provide palliative care services)
NSLHD Referral
https://www.nslhd.health.nsw.gov.au/Palliative-Care/Pages/Outpatient-services.aspx
HammondCare Palliative Care
https://www.hammond.com.au/care/palliative-supportive-care
Northern Sydney Home Nursing.
https://www.nslhd.health.nsw.gov.au/pach/Pages/NSHNS.aspx
Targeted Breast Screening for General Practitioners – which test and where?
Experts from the RNSH Breast Unit provide viewers with a comprehensive discussion aimed at equipping General Practitioners with the ability to assess breast cancer risk, select appropriate screening tests based on individual patient profiles, and navigate referral pathways to local resources with confidence and clarity.
Target Audience:
- General Practitioners
- Nurses, Pharmacists
- Allied Health Professionals
- Other interested Health Professionals
Learning outcomes:
- Determine patient risk for breast cancer
- Order the appropriate screening test for your patient based upon their risk
- Establish referral pathways to appropriate in area resources for selected patients
Speakers:
- Mathilda Wilding, Geneticist
- Katrina Moore, Breast Surgeon
- Sarah Choi, Breast Radiologist
- Jennifer O’Sullivan, Breast Physician
- Dr David Speakman, Breast Surgeon BCAL Diagnostics
Deprescribing Psychotropics
The overuse of antidepressants and psychiatric medications is a growing concern for healthcare and regulatory bodies, including the NDIS Commission and the Australian Commission on Safety and Quality in Health Care. Both the Disability and Aged Care Royal Commissions have called for efforts to reduce this overuse.
Stopping these medications safely has been neglected in psychiatric teaching, leading to significant harm from severe and prolonged withdrawal effects. The Maudsley Deprescribing Guidelines aim to address this gap.
Withdrawal effects are more common and severe than previously recognized, with some people experiencing debilitating protracted withdrawal syndromes. These effects can be mistaken for a relapse or new condition, highlighting the need for better recognition and distinction.
Advances in the science of stopping antidepressants have led to updated UK guidelines on gradual, hyperbolic tapering.
Target Audience: GPs, Nurses, Allied Health Professionals, Pharmacists, any prescribers or clinicians that have regular contact with people using psychotropic medications
Learning outcomes:
- Identify when, why and in whom to stop antidepressants and other psychiatric drugs
- Describe the risks of stopping these medications too quickly
- Distinguish between withdrawal effects from these drugs and relapse of an underlying condition
- Apply the latest principles in safe tapering to stopping these drugs classes, adjusted to the individual patient
Speakers:
Dr. Mark Horowitz MBBS PhD is a Clinical Research Fellow in Psychiatry with the NHS in England and a Visiting Lecturer in Psychopharmacology at King’s College London. He holds a PhD in the neurobiology of depression and antidepressant action.
Dr. Horowitz is the lead author of the Maudsley Deprescribing Guidelines and co-authored the Royal College of Psychiatrists’ guidance on ‘Stopping Antidepressants’. His work has informed NICE guidelines on safe tapering of psychiatric medications. He has published papers in top journals and is an Associate Editor of Therapeutic Advances in Psychopharmacology. His personal experience with psychiatric medication withdrawal has greatly influenced his work.
Resources:
Dr Mark Horowitz Presentation - Deprescribing Psychotropics
RACGP Link to guidelines: Maudlsey Deprescribing Guidelines
Early identification of diabetes and lifestyle intervention
This webinar covered
- Early identification of diabetes
- Management of pre-diabetes
- Strategies to delay disease progression
- Preventative health strategies and lifestyle management including diet, nutrition and exercise.
Speakers:
Dr Rodrigo, Clinical Endocrinologist
Dr Andrea Matthews, General Practitioner
Cassandra Wong, Exercise Physiologist
Jane Freeman, accredited Dietitian
Diagnosis and treatment guidelines for Asthma and COPD Management
Asthma and COPD are common conditions identified and managed in primary care.
There has been a dramatic increase in the number of respiratory inhalers which can be confusion. This education webinar will provide an overview of case definition and spirometric diagnosis as well as asthma and COPD guidelines to assist in the appropriate prescription of respiratory inhalers.
Viewers will learn more about respiratory inhalers and their impact on climate change, as well as low carbon footprint respiratory care, including safe disposal of inhalers
Speakers:
Dr Sophie Timmins, Respiratory and Sleep Medicine Physician, MB BS PhD FRACGP
Dr Timmins is a Staff Specialist at Royal North Shore Hospital and is in private practice at the Sleep and Breathing Specialist Centre.
Dr Katrina Tonga, Respiratory and Sleep Medicine Physician, MBChB PhD FRACP
Dr Tonga is a Staff Specialist at St Vincent’s Hospital and is in private practice at the Sleep and Breathing Specialist Centre.
Melissa Batger, Pharmacist
Melissa is a Senior Pharmacist at Royal North Shore Hospital and is the Cancer Care Leader Clinical Pharmacist.
Speakers are NetZero Respiratory Leads with the Northern Sydney Local Health District, working to reduce the carbon impact of the health sector